Specialized testing
Delivering value beyond the test result
Our commitment to improving patient outcomes propels the development of clinically impactful, patient-focused testing. Supported by clinical physicians and laboratory scientists with unmatched experience and expertise, our assays — several of which are unavailable elsewhere — deliver actionable answers that improve patient lives.
Our data-driven, evidence-based tests provide actionable answers for patients that clarify each patient’s unique healthcare journey.
Specialty testing menu
Collaborations that power innovation
We relentlessly innovate on behalf of patients to build tests of the future to help physicians impact more lives. Mayo Clinic Laboratories scientists and physicians are leaders in their fields and at the forefront of translating new ideas into meaningful solutions. Through groundbreaking collaborations with healthcare companies and diagnostics leaders, we simplify access to new and advanced laboratory tests.
Commitment to education
The exchange of knowledge is a founding principle at Mayo Clinic. In this tradition, we provide a wide range of education offerings and outreach consultation to help you drive continual improvement.
- Regionally based clinical specialists help guide best practices through physician education.
- Access to Mayo Clinic Laboratories' education offerings and Insight articles.
- Many courses offer CME credits.
- Online trainings are available, such as “Dangerous Goods Shipping,” and include printable certificates.
News and updates
The latest
Autoimmune encephalitis (AE) is a rare but serious condition, and accurate diagnosis is critical. Misdiagnosis can lead to unnecessary treatments, delayed care, and preventable complications.
Dr. Bill Morice explores how the data revolution is shaping clinical diagnostics as it drives healthcare transformation at an unprecedented pace.
Mayo Clinic Laboratories is transforming diagnostics with innovations in 2025 that turned research into real-world solutions for better patient care.
Discover an overview of common acronyms that laboratory outreach leaders may encounter in their daily work and links to help you learn more.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent news updates and key advancements shaping the industry in 2025.
PACE/FL - Review the latest evidence, guidelines, strategies, and testing solutions for differentiating metabolic from alcohol-related liver injury.
PACE/FL. This webinar introduces real-time quaking-induced conversion (RT-QuIC) assays that are now available at Mayo Clinic for diagnosing human prion disease.
We wish you a joyful holiday season and look forward to continuing our collaboration in 2026.
Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered due to the upcoming New Year's holiday. To ensure specimen stability and prevent delays, follow the guidelines outlined below for domestic clients and international clients.
Discuss ways to become an effective coach and guide your colleagues and teams toward improvements and successes.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss Protecting Access to Medicare Act (PAMA) reform and the first reported death from alpha-gal syndrome. Later, Dr. Pritt welcomes Chris Garcia, M.D., Mayo Clinic Laboratories’ chief digital innovation officer and medical director of BioPharma Diagnostics, to explore how biopharma diagnostics advance research and development.
April 28, 2025 - Inflammatory bowel disease (IBD) is classified as either Crohn’s disease or ulcerative colitis, based on clinical presentation, endoscopic findings, histopathology, and disease distribution.
November 3, 2025 - In this video, Dr. Andrew McKeon describes how the field of autoimmune neurology testing has changed with the explosion of antibody discovery and discusses the importance of a patient-first, phenotype-based approach.